Cellular Energy Sensor Linked to the Progression of Chronic Kidney Disease

by Colleen Fleiss on  December 8, 2018 at 10:56 PM Research News
RSS Email Print This Page Comment bookmark
Font : A-A+

In chronic kidney disease (CKD) patients failure to sense adenosine monophosphate (AMP) is the important mechanism underlying the inactivity of AMP-activated protein kinase (AMPK), revealed research team from TMDU and Kyushu University.
Cellular Energy Sensor Linked to the Progression of Chronic Kidney Disease
Cellular Energy Sensor Linked to the Progression of Chronic Kidney Disease

Chronic kidney disease (CKD), an affliction characterized by progressive loss of kidney function, affects millions of people worldwide and is associated with multi-organ damage, cardiovascular disease, and muscle wasting. Just like engines, living cells require energy to run, thus the combined millions of cells forming an organ have huge energy requirements. Although the heart has the highest energy needs of all human organs, the kidneys come a close second. Currently, there is no effective treatment to halt this progression.

Adenosine triphosphate (ATP) is the major "fuel" in most living cells and is converted to adenosine monophosphate (AMP) during energy transfer. A specialized energy sensor called 5?-AMP-activated protein kinase (AMPK) detects even the slightest changes in cellular energy by sensing AMP levels, triggering the production of ATP in response to energy depletion. However, AMPK activity is decreased in CKD and the mechanism controlling this dysregulation is unclear. In a recent study published in Kidney International, they outline how they came to this conclusion and what it may mean for CKD patients.

"Metabolites can tell us a lot about what's going on in a cell," explains lead author Hiroaki Kikuchi. "In CKD mice, metabolite profiling showed that despite high levels of AMP, there was a substantial decrease in AMPK activation, leading us to conclude that the AMP-sensing function of AMPK was defective."

Armed with this new information, the researchers tried bypassing the AMP-sensing mechanism to determine whether AMPK could still be activated in CKD mice. By treating the mice with A-769662, an AMPK activator that binds at a different site to AMP, they could significantly attenuate CKD progression and correct associated tissue damage.

Critically, the build-up of waste products in the blood as a result of reduced kidney function was shown to be responsible for the decreased AMP-sensing activity of AMPK. "Our findings suggest that energy depletion, CKD progression, and the accumulation of toxic metabolites form a vicious cycle in CKD patients," says co-corresponding author Eisei Sohara. "However, AMPK activation via AMP-independent mechanisms can break this cycle and represents a novel therapeutic approach for the treatment of CKD."

Source: Eurekalert

Post a Comment

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
Notify me when reply is posted
I agree to the terms and conditions
Advertisement

Recommended Reading

More News on:

Chronic Renal Failure Glomerulonephritis Urinary Stones In Children Vesico-Ureteric Reflux Causing UTI in Children Hydronephrosis / Antenatal Counseling Kidney Disease Kidney Kidney Health Stones in Urinary Tract Renal Tubular Acidosis 

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Stay Connected

  • Available on the Android Market
  • Available on the App Store

News Category

News Archive